Bioresorbable vascular scaffold thrombosis in an all-comer patient population: Single-center experience

Journal of Invasive Cardiology

Volumn 27, Issue 2, 2015, Pages 85-92

  Azzalini, Lorenzo ^a   L'Allier, Philippe L ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

acute coronary syndrome; bioresorbable vascular scaffold; percutaneous coronary intervention; scaffold thrombosis; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; EVEROLIMUS; ZOTAROLIMUS; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIORESORBABLE VASCULAR STENT; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SURGICAL THROMBECTOMY; VASCULAR CLOSURE DEVICE; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; CASE REPORT; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; GRAFT OCCLUSION, VASCULAR; MIDDLE AGED; PATHOLOGY; PROSTHESIS DESIGN; REOPERATION; RETROSPECTIVE STUDY; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; ADULT; AGED; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; EVEROLIMUS; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PROSTHESIS DESIGN; REOPERATION; RETROSPECTIVE STUDIES; SIROLIMUS; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84922598677     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sarno G, Bruining N, Onuma Y, et al. Morphological and function-Al evaluation of the bioresorption of the bioresorbable everolim-us-eluting vascular scaffold using IVUS, echogenicity and vasomo-Tion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging. 2012;28(1):51-58
2. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of ves-sel wall changes following the implantation of the Absorb ever-olimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9(11):1271-1284
3. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J. 2013;35(12):765-776
4. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in cor-onary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351
5. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?. Cir-culation. 2011;123(7):779-797
6. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolim-us-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897-910
7. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endo-Thelialization. Circulation. 2007;115(18):2435-2441. Epub 2007 Apr 16
8. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202. Epub 2006 May 5
9. Schultz RK. REVA Medical, Inc. Bioresorbable stent. Presented at: Cardiovascular Revascularization Therapies Conference. Washing-Ton, DC. March 7-9, 2007
10. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. Heart. 2003;89(6):651-656
11. Seifert B, Romaniuk P, Groth T. Bioresorbable, heparinized polymers for stent coating: in vitro studies on heparinization efficiency, main-Tenance of anticoagulant properties and improvement of stent haemocompatibility. J Mater Sci Mater Med. 1996;7:465-469
12. Dörler J, Frick M, Hilber M, et al. Coronary stents cause high veloc-ity fluctuation with a flow acceleration and flow reduction in jailed branches: an in vitro study using laser-Doppler anemometry. Bior-heology. 2012;49(5-6):329-340
13. Gogas BD, King SB, Timmins LH, et al. Biomechanical assessment of fully bioresorbable devices. JACC Cardiovasc Interv. 2013;6(7):760-761
14. LaDisa JF, Olson LE, Guler I, et al. Stent design properties and deploy-ment ratio influence indexes of wall shear stress: a three-dimension-Al computational fluid dynamics investigation within a normal artery. J Appl Physiol (1985). 2004;97(1):424-430
15. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: patho-physiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59(15):1337-1349
16. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103(23):2816-2821
17. Ishibashi Y, Onuma Y, Muramatsu T, et al. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIn-Tervention. 2014;10(4):449-457
18. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9(9):1036-1041
19. Abizaid A. First report on the pivotal DESolve Nx trial: 6-month clini-cal and multimodality imaging results. Presented at: EuroPCR. Paris, France. May 21-24, 2013
20. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting biore-sorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35(12):777-786. Epub 2014 Jan 6
21. Haude M. Two-year clinical data and multi-modality imaging re-sults up to 1-year follow-up of the BIOSOLVE-I study with the pa-clitaxel-eluting bioabsorbable magnesium scaffold (DREAMS). Pre-sented at: EuroPCR. Paris, France. May 21-24, 2013
22. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study "Prague 19." Eur Heart J. 2014;35(12):787-794. Epub 2014 Jan 12
23. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coro-nary implantation of the fully resorbable polymeric everolimus-elut-ing scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6(10):999-1009
24. Costa RA. REVA ReZolve clinical program update. Presented at: Transcath-eter Cardiovascular Therapeutics. Miami Beach, FL. October 22-28, 2012
25. Wiebe J, Möllmann H, Most A, et al. Short-Term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103(2):141-148. Epub 2013 Oct 18
26. Kajiya T, Liang M, Sharma RK, et al. Everolimus-eluting bioresorb-Able vascular scaffold (BVS) implantation in patients with ST-seg-ment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9(4):501-504
27. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and sec-ond-generation drug-eluting stents: results from a registry of 18, 334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-1274
28. Jaguszewski M, Wyss C, Alibegovic J, Lüscher TF, Templin C. Acute thrombosis of bioabsorbable scaffold in a patient with acute coro-nary syndrome. Eur Heart J. 2013;34(27):2046. Epub 2013 Feb 17
29. Fernández-Rodríguez D, Brugaletta S, Otsuki S, Sabaté M. Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?. EuroInter-vention. 2014;10(5):600; discussion 600
30. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart As-sociation Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-e122. Epub 2011 Nov 7
31. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volun-Teers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32(1):161-170